Biohaven (BHVN) EBT (2021 - 2026)
Biohaven (BHVN) posted EBT of -$130.3 million for Q1 2026, up 10.29% sequentially from -$145.2 million in Q4 2025, and up 41.08% YoY from -$92.3 million in Q1 2025.
Biohaven (BHVN) EBT (2021 - 2026) Analysis & Trends
Biohaven has reported EBT for 6 years, with the latest figure at -$130.3 million in Q1 2026.
- Quarterly EBT rose 41.08% year-over-year to -$130.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$646.6 million (up 27.17% YoY) and the FY2025 annual result came in at -$737.4 million, up 12.81% from the prior year.
- EBT climbed to -$130.3 million in Q1 2026 per BHVN's latest filing, from -$145.2 million in the prior quarter.
- Over five years, EBT peaked at -$67.6 million in Q3 2022 and troughed at -$319.6 million in Q2 2024.
- A 5-year average of -$158.4 million and a median of -$160.4 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2023: EBT slumped 335.47% in 2022, then surged 55.28% in 2023.
- Over 5 years, EBT stood at -$215.2 million in 2022, then soared by 32.19% to -$146.0 million in 2023, then decreased by 27.97% to -$186.8 million in 2024, then increased by 22.27% to -$145.2 million in 2025, then rose by 10.29% to -$130.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$130.3 million, -$145.2 million, and -$173.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Biohaven | 2.21 Bn | 1.94 Bn | - | -136.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136.92 Mn |
| Mar 31, 2026 | -130.26 Mn |
| Dec 31, 2025 | -145.20 Mn |
| Sep 30, 2025 | -173.22 Mn |
| Jun 30, 2025 | -197.89 Mn |
| Mar 31, 2025 | -221.07 Mn |
| Dec 31, 2024 | -186.80 Mn |
| Sep 30, 2024 | -160.36 Mn |
| Jun 30, 2024 | -319.59 Mn |
| Mar 31, 2024 | -178.94 Mn |
| Dec 31, 2023 | -145.97 Mn |
| Sep 30, 2023 | -105.86 Mn |
| Jun 30, 2023 | -88.17 Mn |
| Mar 31, 2023 | -69.55 Mn |
| Dec 31, 2022 | -215.25 Mn |
| Sep 30, 2022 | -67.64 Mn |
| Jun 30, 2022 | -197.18 Mn |
| Mar 31, 2022 | -89.78 Mn |
| Dec 31, 2021 | -49.43 Mn |
| Sep 30, 2021 | -55.50 Mn |